FBR Capital analyst Ed White says that while the dalantercept failed Phase II study is "disappointing," his focus remains on luspatercept, which is being studied in beta-thalassemia and myelodysplastic syndrome. Celgene (CELG) estimates peak sales potential of over $2B for luspatercept, which could translate into more than $400M in revenue for Acceleron Pharma (XLRN), White tells investors in a research note. He thinks luspatercept could be brought to market by 2019. White's price target for Acceleron remains $63 as he had only a 15% probability of approval and a low revenue estimate for dalantercept. The analyst reiterates an Outperform rating on the shares.